IGF-1 LR3: A Research Overview
Why two deliberate changes to the IGF-1 sequence — an N-terminal extension and an Arg-3 substitution — produced a research reagent that engages IGF-1R while escaping the binding-protein family. Educational reference.
For research use only. Not for human consumption. This article is educational reference material. It is not medical advice and is not a recommendation to use any substance.
IGF-1 LR3: Structure, Classification, and Regulatory Status
Most insulin-like growth factor-1 (IGF-1) analogs studied in laboratories are variations on a single problem: how to present the ligand to its receptor without a family of binding proteins intercepting it first. IGF-1 LR3 — formally Long Arginine-3 Insulin-like Growth Factor-1 — is one of the most widely catalogued solutions to that problem. Rather than restate the generic profile of the compound, this overview is organized around the two deliberate sequence changes that define it, the binding-protein logic those changes were built to address, and the practical role the molecule plays as a defined reagent in receptor biology.
Figure: chemical structure of IGF-1 LR3.
The two engineered changes
Native mature human IGF-1 is a 70-amino acid single-chain polypeptide of roughly 7.6 kilodaltons, folded by three intramolecular disulfide bonds into a compact tertiary structure homologous to proinsulin. IGF-1 LR3 differs from it in exactly two respects, and both are intentional [1].
The first change is an addition. A 13-residue peptide sequence — the "Long" portion of the name — is fused to the amino terminus of the molecule, producing an 83-amino acid chain of approximately 9.1 kilodaltons. This extension is not present in any endogenous form of circulating IGF-1.
The second change is a single-residue substitution. At position 3 of the mature sequence, the glutamic acid residue found in native IGF-1 is replaced with arginine — the "Arginine-3," or R3, that completes the name. Francis and colleagues characterized this class of substituted analogs in the early 1990s and established that these N-terminal-region modifications, rather than changes to the receptor-contact surface, govern the molecule's altered binding behavior [1, 2]. The receptor-binding epitope itself is left structurally intact.
Why decoupling from binding proteins was the design goal
The purpose of both changes becomes clear only against the biology of the IGF system. Circulating IGF-1 does not travel freely. It is bound by a family of at least six high-affinity carriers, the IGF-binding proteins (IGFBP-1 through IGFBP-6), which regulate the ligand's half-life, tissue distribution, and access to its receptor. Under typical physiological conditions an estimated 98% of circulating IGF-1 is complexed with one or more IGFBPs at any given moment [3].
For an investigator, that sequestration is a confound. When native IGF-1 is introduced into a biological system that still contains IGFBPs — which is nearly every serum-supplemented cell culture and every intact animal — a large and variable fraction of the added ligand is captured before it can reach the type 1 IGF receptor (IGF-1R). Because several IGFBPs bind IGF-1 with an affinity equal to or greater than that of IGF-1R itself, the receptor is effectively competing with the carriers for its own ligand.
The Long-R3 modifications were engineered to remove that competition. The N-terminal region of IGF-1 forms part of the IGFBP-contact surface, and altering it disrupts binding-protein engagement far more than receptor engagement. Studies from the 1990s reported that the affinity of Long R3 IGF-1 for IGFBPs — including IGFBP-1, IGFBP-2, and IGFBP-3 — is on the order of three orders of magnitude lower than that of native IGF-1, while high-affinity binding at the IGF-1R extracellular domain is preserved [1, 4].
Findings from research models do not establish safety or efficacy in humans. Sparta Labs makes no claims about the use of this compound.
Tomas and colleagues reported that this decoupling had a measurable functional consequence: in comparative infusion studies, analogs that bound poorly to IGFBPs were associated with substantially greater potency per unit mass than equimolar native IGF-1 in the models examined [4]. The reduced-sequestration profile is what makes the analog attractive as a defined, minimally-buffered probe. The reasoning behind that receptor-versus-carrier competition is examined in more depth in the IGF-1 LR3 mechanism of action article.
Where IGF-1 LR3 sits in the peptide-hormone taxonomy
IGF-1 LR3 is classified as a synthetic analog of IGF-1, a member of the insulin superfamily of peptide growth factors. That superfamily — insulin, IGF-1, IGF-2, relaxins, and related peptides — is unified by a conserved architecture of disulfide-bonded A and B domains connected by a C domain, and by signaling through the insulin-receptor family of receptor tyrosine kinases.
Within that family, the analog's defining pharmacological trait is not receptor selectivity. Both native IGF-1 and IGF-1 LR3 engage IGF-1R preferentially. The distinction is the degree to which extracellular binding proteins can intercept the ligand before it acts. At concentrations optimized for IGF-1R research, receptor selectivity dominates the pharmacological profile.
At markedly higher concentrations, the picture broadens. Andersen and colleagues (2007) reported that in HEK293 cell culture, Long R3 IGF-1 activated insulin-receptor (IR) signaling at concentrations lower than the molecule's low intrinsic IR affinity alone would predict — an observation the authors attributed to heterotetrameric IGF-1R/IR hybrid receptors rather than to direct high-affinity IR binding [5]. That report also underlies the molecule's frequent role as a serum-free supplement in recombinant-protein cell culture. Growth-hormone-axis analogs that reach the IGF-1 node through an entirely different receptor route are surveyed in the tesamorelin research overview, which describes a GHRH analog acting upstream of IGF-1 rather than at the receptor itself.
The molecule as a defined reagent, and where to find it
IGF-1 LR3 is used as a research reagent in non-clinical contexts. It does not hold approval from the United States Food and Drug Administration (FDA), nor from any comparable international authority, for human therapeutic use. It has been catalogued in the FDA's Unique Ingredient Identifier (UNII) database under identifier M9L22Y19H9 — an assignment that reflects chemical characterization of a defined substance and confers no regulatory review or approval for human use.
The distinction between this research analog and the approved clinical molecule in the same family is worth stating precisely. Mecasermin (Increlex) is recombinant human IGF-1 carrying the native 70-amino acid sequence, approved under NDA 021839 for growth failure in children with severe primary IGF-1 deficiency [6]. Mecasermin carries none of the LR3 modifications; the two molecules are structurally and pharmacologically distinct, and mecasermin's approval speaks to native-sequence IGF-1, not to the Long R3 analog.
The design itself traces to Australian research programs of the late 1980s and early 1990s, with the compound subsequently produced and supplied as a research reagent by GroPep Ltd of Adelaide — a provenance detailed in the IGF-1 LR3 discovery and regulatory history article, alongside the IGF-1 LR3 published research summary for those tracing the primary literature. Laboratories evaluating material for reagent use can review specifications and place an order on the IGF-1 LR3 product page.
References
-
Francis GL, McNeil KA, Wallace JC, Ballard FJ, Bhatt M. Characterisation of insulin-like growth factor (IGF) analogues with modified affinities for IGF binding proteins. J Mol Endocrinol. 1992;8(3):213-23. PMID: 1534540. DOI: 10.1677/jme.0.0080213
-
Ballard FJ, Ross M, Upton FM, Francis GL. Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively. Biochem J. 1988;249(3):721-6. PMID: 2833230. DOI: 10.1042/bj2490721
-
Allard JB, Duan C. IGF-binding proteins: why do they exist and why are there so many? Front Endocrinol (Lausanne). 2018;9:117. PMID: 29686647. DOI: 10.3389/fendo.2018.00117
-
Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996;150(1):77-84. PMID: 8708565. DOI: 10.1677/joe.0.1500077
-
Andersen DC, Storling J, Lindberg AM, et al. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Mol Biotechnol. 2007;34(2):201-12. PMID: 17172665. DOI: 10.1385/MB:34:2:201
-
US Food and Drug Administration. Increlex (mecasermin) injection: NDA 021839 prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021839s033lbl.pdf
Disclaimer. Statements in this article have not been evaluated by the Food and Drug Administration. This compound is not intended to diagnose, treat, cure, or prevent any disease. Sparta Labs sells research-use-only materials. Content is provided for educational and informational purposes only and does not constitute medical advice. Consult a qualified medical professional for any health concerns.
Frequently asked questions
What are the two structural changes that define IGF-1 LR3?
IGF-1 LR3 differs from native 70-amino acid human IGF-1 by two deliberate modifications. It carries a 13-residue N-terminal extension (the "Long" element), producing an 83-amino acid chain of about 9.1 kilodaltons, and an arginine substitution replacing glutamic acid at position 3 (the "R3" element). Both changes sit in the N-terminal region rather than on the receptor-contact surface.
Why was IGF-1 LR3 engineered to bind IGF-binding proteins poorly?
In typical conditions an estimated 98% of circulating IGF-1 is held by a family of at least six IGF-binding proteins, which compete with the receptor for the ligand. Reported studies indicate the N-terminal modifications lower IGF-1 LR3's affinity for IGFBPs by roughly three orders of magnitude while preserving IGF-1R binding, which is why investigators use it as a minimally-sequestered reagent.
Is IGF-1 LR3 the same as mecasermin (Increlex)?
No. Mecasermin (Increlex) is recombinant human IGF-1 with the native 70-amino acid sequence and holds FDA approval under NDA 021839 for growth failure in children with severe primary IGF-1 deficiency. IGF-1 LR3 carries the Long-R3 modifications, is structurally and pharmacologically distinct, and is a non-clinical research reagent with no such approval.
Does IGF-1 LR3 interact with the insulin receptor?
At concentrations optimized for IGF-1R research, IGF-1 LR3 is preferentially selective for IGF-1R. Andersen and colleagues (2007) reported that at higher concentrations in HEK293 culture it activated insulin-receptor signaling more readily than its low intrinsic IR affinity would predict, an effect the authors attributed to IGF-1R/IR hybrid receptors rather than direct IR binding.